ORCID as entered in ROS

Select Publications
2006, 'Identification Of Tumour Suppressor Genes In Epithelial Ovarian Cancer Using Microcell Mediated Chromosome Transfer', International Journal of Gynecological Cancer, 16, pp. 605 - 605, http://dx.doi.org/10.1136/ijgc-00009577-200610001-00023
,2006, 'Intra Tumour Genetic Heterogeneity In Epithelial Ovarian Cancer: The Implications For Clinical Diagnostics', International Journal of Gynecological Cancer, 16, pp. 606 - 606, http://dx.doi.org/10.1136/ijgc-00009577-200610001-00025
,2006, 'Targeting In Vivo Delivery Of Sirnas To Study The Role Of Klf6 In Epithelial Ovarian Cancer', International Journal of Gynecological Cancer, 16, pp. 605 - 605, http://dx.doi.org/10.1136/ijgc-00009577-200610001-00022
,2005, 'Complex CGH alterations on chromosome arm 8p at candidate tumor suppressor gene loci in breast cancer cell lines', Cancer Genetics and Cytogenetics, 160, pp. 134 - 140, http://dx.doi.org/10.1016/j.cancergencyto.2004.12.007
,2004, 'Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutations', British Journal of Cancer, 91, pp. 1911 - 1915, http://dx.doi.org/10.1038/sj.bjc.6602239
,2004, 'Common origins of MDA-MB-435 cells from various sources with those shown to have melanoma properties', Clinical and Experimental Metastasis, 21, pp. 543 - 552, http://dx.doi.org/10.1007/s10585-004-3759-1
,2004, 'LCC15-MB cells are MDA-MB-435: A review of misidentified breast and prostate cell lines', Clinical and Experimental Metastasis, 21, pp. 535 - 541, http://dx.doi.org/10.1007/s10585-004-4117-z
,2004, 'Candidate tumor-suppressor genes on chromosome arm 8p in early-onset and high-grade breast cancers', Oncogene, 23, pp. 5697 - 5702, http://dx.doi.org/10.1038/sj.onc.1207740
,2004, 'Histopathology, FIGO Stage, and BRCA Mutation Status of Ovarian Cancers from the Gilda Radner Familial Ovarian Cancer Registry', International Journal of Gynecological Pathology, 23, pp. 29 - 34, http://dx.doi.org/10.1097/01.pgp.0000101083.35393.cd
,2003, 'BRCA1/2 mutation status influences somatic genetic progression in inherited and sporadic epithelial ovarian cancer cases', Cancer Research, 63, pp. 417 - 423
,2001, 'DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis', Human Molecular Genetics, 10, pp. 3001 - 3007, http://dx.doi.org/10.1093/hmg/10.26.3001
,2001, 'Ovarian cancer survival in Ashkenazi Jewish patients with BRCA1 and BRCA2 mutations', European Journal of Surgical Oncology, 27, pp. 278 - 281, http://dx.doi.org/10.1053/ejso.2000.1097
,2000, 'Frequent loss of BRCA1 mRNA and protein expression in sporadic ovarian cancers', International Journal of Cancer, 87, pp. 317 - 321, http://dx.doi.org/10.1002/1097-0215(20000801)87:3<317::AID-IJC2>3.0.CO;2-B
,2000, 'Ovarian carcinoma in situ with germline BRCA1 mutation and loss of heterozygosity at BRCA1 and TP53', Journal of the National Cancer Institute, 92, pp. 1088 - 1091, http://dx.doi.org/10.1093/jnci/92.13.1088
,2000, 'Histopathology of familial ovarian tumors in women from families with and without germline BRCA1 mutations', Human Pathology, 31, pp. 1420 - 1424, http://dx.doi.org/10.1016/S0046-8177(00)80014-3
,2000, 'Idiopathic slow-transit constipation is not associated with mutations of the RET proto-oncogene or GDNF', Diseases of the Colon and Rectum, 43, pp. 851 - 857, http://dx.doi.org/10.1007/BF02238026
,2000, 'Primary ovarian dysgerminoma in a patient with a germline BRCA1 mutation', International Journal of Gynecological Pathology, 19, pp. 390 - 394, http://dx.doi.org/10.1097/00004347-200010000-00017
,1999, 'Increased frequency of TP53 mutations in BRCAI and BRCA2 ovarian tumours', Genes Chromosomes and Cancer, 25, pp. 91 - 96, http://dx.doi.org/10.1002/(SICI)1098-2264(199906)25:2<91::AID-GCC3>3.0.CO;2-5
,1999, 'High frequency of germ-line BRCA2 mutations among Hungarian male breast cancer patients without family history', Cancer Research, 59, pp. 995 - 998
,1999, 'Genotype and intellectual phenotype in untreated phenylketonuria patients', Pediatric Research, 45, pp. 474 - 481, http://dx.doi.org/10.1203/00006450-199904010-00004
,1998, 'Identification of germ-line E-cadherin mutations in gastric cancer families of European origin', Cancer Research, 58, pp. 4086 - 4089
,1997, 'Analysis of BRCA1 and BRCA2 mutations in hungarian families with breast or breast-ovarian cancer [4]', American Journal of Human Genetics, 60, pp. 1242 - 1246
,1997, 'A breast/ovarian cancer patient with germline mutations in both BRCA1 and BRCA2', Nature Genetics, 15, pp. 14 - 15, http://dx.doi.org/10.1038/ng0197-14
,1996, 'Single-tube chemical cleavage of mismatch: Successive treatment with hydroxylamine and osmium tetroxide', Biotechniques, 21, pp. 216 - 220, http://dx.doi.org/10.2144/96212bm10
,1996, 'In vivo disposal of phenylalanine in phenylketonuria: A study of two siblings', JOURNAL OF INHERITED METABOLIC DISEASE, 19, pp. 595 - 602, http://dx.doi.org/10.1007/BF01799832
,1995, 'Polymorphism in the 3′ untranslated region of the phenylalanine hydroxylase gene detected by enzyme mismatch cleavage: evolution of haplotypes', Human Genetics, 96, pp. 741 - 743, http://dx.doi.org/10.1007/BF00210312
,1995, 'Characterization of phenylalanine hydroxylase alleles in untreated phenylketonuria patients from Victoria, Australia: Origin of alleles and haplotypes', American Journal of Human Genetics, 56, pp. 1034 - 1041
,1995, 'Genotype/phenotype correlations: Intellectual phenotypes in untreated PKU patients', International Pediatrics, 10, pp. 92 - 94
,1995, 'Mutations Ivs4nt1, 47delCT, and G148S identified in the phenylalanine hydroxylase gene by RT‐PCR of illegitimate transcripts and chemical cleavage of mismatch', Human Mutation, 6, pp. 250 - 251, http://dx.doi.org/10.1002/humu.1380060309
,1993, 'Analysis of Sequence Contexts Flanking T·G Mismatches Leads to Predictions about Reactivity of the Mismatched T to Osmium Tetroxide', DNA and Cell Biology, 12, pp. 945 - 949, http://dx.doi.org/10.1089/dna.1993.12.945
,1993, 'Comparison of genotype and intellectual phenotype in untreated PKU patients', Journal of Medical Genetics, 30, pp. 401 - 405, http://dx.doi.org/10.1136/jmg.30.5.401
,1993, 'Molecular analysis of contiguous exons of the phenylalanine hydroxylase gene: Identification of a new PKU mutation', Journal of Medical Genetics, 30, pp. 228 - 231, http://dx.doi.org/10.1136/jmg.30.3.228
,1992, 'CpG hotspot causes second mutation in codon 408 of the phenylalanine hydroxylase gene', Human Genetics, 90, pp. 147 - 148, http://dx.doi.org/10.1007/BF00210760
,1992, 'Complete mutation detection using unlabeled chemical cleavage', Human Mutation, 1, pp. 63 - 69, http://dx.doi.org/10.1002/humu.1380010110
,1992, 'Illegitimate transcription of phenylalanine hydroxylase for detection of mutations in patients with phenylketonuria', Human Mutation, 1, pp. 154 - 158, http://dx.doi.org/10.1002/humu.1380010211
,1991, 'A SPONTANEOUS MUTATION CAUSING UNSTABLE Hb HAMMERSMITH: DETECTION OF THE β42 TTT→TCT CHANGE BY CCM AND DIRECT SEQUENCING', British Journal of Haematology, 79, pp. 127 - 129, http://dx.doi.org/10.1111/j.1365-2141.1991.tb08026.x
,1991, 'Simultaneous screening for β-thalassemia mutations by chemical cleavage of mismatch', Genomics, 11, pp. 48 - 53, http://dx.doi.org/10.1016/0888-7543(91)90100-S
,2025, 'Co-Amplification Of CCNE1 And AKT2 As Prognostic Biomarker And Therapeutic Target In Tubo-Ovarian High-Grade Serous Carcinoma', in International Journal of Gynecological Cancer, Elsevier BV, pp. 101684 - 101684, http://dx.doi.org/10.1016/j.ijgc.2025.101684
,2024, '752P Clinical and molecular predictors of outcome in patients with tubo-ovarian high-grade serous carcinoma and exceptional survival', in Annals of Oncology, Elsevier BV, pp. S571 - S571, http://dx.doi.org/10.1016/j.annonc.2024.08.813
,2022, 'Environmental factors associated with residual disease after ovarian cancer primary cytoreduction surgery', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, LA, New Orleans, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), LA, New Orleans, 08 April 2022 - 13 April 2022, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000892509508075&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2021, 'Abstract 1045: Combined targeting of actin/tropomyosin and microtubules underlies a potential treatment strategy of epithelial ovarian cancer with cell-cycle dependent synergy', in Cancer Research, American Association for Cancer Research (AACR), pp. 1045 - 1045, http://dx.doi.org/10.1158/1538-7445.am2021-1045
,2021, 'Combined targeting of actin/tropomyosin and microtubules underlies a potential treatment strategy of epithelial ovarian cancer with cell-cycle dependent synergy.', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000680263503257&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2020, 'Abstract A03: PrOTYPE (Predictor of high-grade-serous Ovarian carcinoma molecular subTYPE): The development and validation of a clinical-grade consensus classifier for the molecular subtypes of high-grade serous tubo-ovarian cancer', in Clinical Cancer Research, American Association for Cancer Research (AACR), pp. A03 - A03, http://dx.doi.org/10.1158/1557-3265.ovca19-a03
,2020, 'Abstract B37: Germline mutations in new susceptibility genes for non-high-grade serous ovarian cancer', in Clinical Cancer Research, American Association for Cancer Research (AACR), pp. B37 - B37, http://dx.doi.org/10.1158/1557-3265.ovca19-b37
,2020, 'Abstract IA05: Molecular analysis of exceptional response in high-grade serous ovarian cancer', in Clinical Cancer Research, American Association for Cancer Research (AACR), pp. IA05 - IA05, http://dx.doi.org/10.1158/1557-3265.ovca19-ia05
,2020, 'Abstract IA12: The Ovarian Tumour Tissue Analysis Consortium: Stratified Prognosis of Ovarian Tumors (OTTA-SPOT) signature for high-grade serous ovarian cancer', in Clinical Cancer Research, American Association for Cancer Research (AACR), pp. IA12 - IA12, http://dx.doi.org/10.1158/1557-3265.ovca19-ia12
,2019, 'Molecular analysis of exceptional response in high-grade serous ovarian cancer.', in CLINICAL CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, GA, Atlanta, pp. 17 - 18, presented at AACR Special Conference on Advances in Ovarian Cancer Research, GA, Atlanta, 13 September 2019 - 16 September 2019
,2019, 'PrOTYPE (Predictor of high-grade-serous Ovarian carcinoma molecular subTYPE): The development and validation of a clinical-grade consensus classifier for the molecular subtypes of high-grade serous tubo-ovarian cancer.', in CLINICAL CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, GA, Atlanta, pp. 38 - 38, presented at AACR Special Conference on Advances in Ovarian Cancer Research, GA, Atlanta, 13 September 2019 - 16 September 2019
,2019, 'Abstract 2722: The genomic landscape of high-grade serous ovarian cancer in long-term survivors', in Molecular and Cellular Biology / Genetics, American Association for Cancer Research, pp. 2722 - 2722, presented at Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA, http://dx.doi.org/10.1158/1538-7445.sabcs18-2722
,2019, 'SATB2 Demonstrates Superior Accuracy and PAX8 Superior Specificity in Differentiating Primary Ovarian Mucinous Neoplasm from Lower Gastrointestinal Metastasis Comparing to Traditional Markers', in LABORATORY INVESTIGATION, NATURE PUBLISHING GROUP, MD, National Harbor, presented at 108th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) - Unlocking Your Ingenuity, MD, National Harbor, 16 March 2019 - 21 March 2019
,